Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

PJ Online | PJ Letters: Drug misuse

Home > PJ  > Letters | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 268 No 7186 p243-245
23 February 2002

This page
Reprint
Photocopy

Letters

Letters are available in a single PDF* file (60K)


  Community pharmacy
  POM-to-P
  Drug misuse
  Careers
  The Profession
  The Society
  The Council


Letters to the Editor

  * PDF files on PJ Online require Acrobat Reader 4 or later.

Drug misuse

Local initiatives can have a major impact

From Mrs D. K. Roberts, FRPharmS

A small section of the otherwise excellent paper (PDF* 70K) from Pates et al (PJ, 9 February, p179) requires clarification.

In the discussion section the authors state that, in 1998, Pfizer withdrew Sleepia (a liquid-filled, soft gelatin capsule containing diphenhydramine) because of pressure originating from a letter to Addiction. This statement is incorrect. The letter to Addiction was wrongly referenced in the Pates et al paper. It should have been cited as "Roberts K, Gruer L, Gilhooly T. Misuse of diphenhydramine soft gel capsules (Sleepia): a cautionary tale from Glasgow (letter). Addiction 1999;94:1575?8". It actually describes the sequence of events that ultimately resulted in the withdrawal of Sleepia from the UK market in 1998. By the time the letter was published, the product had been unavailable for some time. It was the quick thinking and rapid reporting by community pharmacists in Glasgow that alerted the Greater Glasgow Health Board and the Medicines Control Agency to the abuse potential of the product.

Sleepia was launched in the UK in May 1997. Immediately following the broadcast of a television advertisement for the product, community pharmacists in Glasgow contacted me expressing concern that Sleepia was being requested by name by "methadone patients". At that point I alerted my colleagues Dr Laurence Gruer and Dr Tom Gilhooly. In addition. I wrote a letter to The Pharmaceutical Journal (PJ, 30 August 1997, p330) and Dr Gruer and I both wrote to the company. Our letter resulted in a firm rebuttal by the company that there was any problem. It was only when the local Glasgow press took up the story that representatives of the company visited Glasgow, spoke with my colleagues and officials of the health board, and reluctantly recognised that our concerns were genuine. They subsequently agreed to withdraw the product in Glasgow (PJ, 18 October 1997, p636) and later in the UK (PJ, 31 January 1998, p153).

Pates et al note in their paper that most pharmacists are aware of the misuse of OTC products and are working to curb the problem. However, individual efforts are likely to have limited impact.

Improved communication between community pharmacists, GPs, community addiction teams and the general public is essential in the implementation of urgently needed national policies. Indeed, as demonstrated by the Glasgow experience with Sleepia, local initiatives can sometimes result in a major impact at a national level.

Kay Roberts
Area Pharmacy Specialist — Drug Misuse
Greater Glasgow Primary Care NHS Trust

 

Mrs Roberts's letter has arisen partly out of an error introduced into Pates et al's paper during editing in our offices, for which we apologise. Pates et al did in fact cite the Addiction reference correctly in their original copy. The wrong year appeared in the printed version.—EDITOR.

 

Previous Topic (POM-to-P)
Next Topic (Careers)
Send your letter to The Editor

Back to Top

Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal

Citation: The Pharmaceutical Journal URI: 20006083

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.